Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)

Trial Profile

Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Regorafenib (Primary) ; Clobetasol
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms ReDOS
  • Most Recent Events

    • 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 25 Apr 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.
    • 25 Jan 2017 Planned End Date changed from 1 Feb 2018 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top